Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Res ; 81(3): 531-536, 2017 03.
Article in English | MEDLINE | ID: mdl-27886192

ABSTRACT

BACKGROUND: Infantile Refsum disease (IRD), a peroxisomal disease with defective phytanic acid oxidation, causes neurological impairment and development delay. Insulin-like growth factor-1 (IGF-1) regulates child development and to understand molecular mechanism(s) of IRD, we examined the effect of phytanic acid (PA) on IGF-1 activity. METHODS: Bromodeoxyuridine (BrdU) incorporation was measured in rat aortic smooth muscle cell (SMC) cultures following treatment with fetal bovine serum (FBS), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) or IGF-1 in the absence or presence of PA. Gene expression and protein contents of IGF-1 receptor (IGF-1R) and PDGF receptor (PDGFR) were examined using quantitative PCR and western blotting. RESULTS: PA inhibited mitogenic activities of FBS, PDGF and IGF-1 with more pronounced effect on IGF-1-induced bromodeoxyuridine (BrdU) incorporation. Palmitic acid or lignoceric acids did not inhibit IGF-1 activity. PA had no effect on PDGFR mRNA/protein levels but markedly increased IGF-1R mRNA levels. PA and nitric oxide (NO) markedly decreased IGF-1R protein. L-NAME, a NO synthase inhibitor and DAPT, a γ-secretase inhibitor, alleviated PA-induced decrease in IGF-1R protein. Both PA and NO donor increased γ-secretase activity which was alleviated by L-NAME. CONCLUSION: This study demonstrates that PA attenuates IGF-1 activity possibly through IGF-1R impairment and NO-mediated modulation of γ-secretase activity.


Subject(s)
Amyloid Precursor Protein Secretases/metabolism , Aorta/metabolism , Insulin-Like Growth Factor I/metabolism , Nitric Oxide/metabolism , Phytanic Acid/pharmacology , Refsum Disease, Infantile/physiopathology , Animals , Cells, Cultured , Disease Models, Animal , Dose-Response Relationship, Drug , Fibroblast Growth Factor 2/metabolism , Male , Muscle, Smooth, Vascular/metabolism , Platelet-Derived Growth Factor/metabolism , Rats , Rats, Wistar , Receptor, IGF Type 1/metabolism , Receptors, Platelet-Derived Growth Factor/metabolism , Refsum Disease, Infantile/metabolism
2.
J Hum Genet ; 52(7): 599-606, 2007.
Article in English | MEDLINE | ID: mdl-17534573

ABSTRACT

Mutations in 12 different PEX genes can cause a generalized peroxisomal biogenesis disorder with clinical phenotypes ranging from Zellweger syndrome to infantile Refsum disease. To identify the specific PEX gene to be sequenced, complementation analysis is first performed in fibroblasts using catalase immunofluorescence. A patient with a relatively mild phenotype of infantile cholestasis, hypotonia and motor delay had elevated plasma very long-chain fatty acids and bile acid precursors, but fibroblast studies revealed normal or only mildly abnormal peroxisomal parameters and mosaic catalase immunofluorescence. This mosaicism persisted even when the incubation temperature was increased from 37 degrees C to 40 degrees C, a maneuver previously shown to abolish mosaicism by exacerbating peroxisomal dysfunction. As mosaicism precludes complementation analysis, a candidate gene approach was employed. After PEX1 sequencing was unrewarding, PEX12 sequencing revealed homozygosity for a novel c.102A>T (p.R34S) missense mutation affecting a partially conserved residue in the N-terminal region important for localization to peroxisomes. Transfection of patient fibroblasts with wild-type PEX12 cDNA confirmed that a PEX12 defect was the basis for the PBD. Homozygosity for c.102A>T was identified in a second patient of similar ethnic origin also presenting with a mild phenotype. PEX12 is a highly probable candidate gene for direct sequencing in the context of a mild clinical phenotype with mosaicism and minimally abnormal peroxisomal parameters in fibroblasts.


Subject(s)
Catalase/metabolism , Fibroblasts/chemistry , Fibroblasts/metabolism , Membrane Proteins/genetics , Mosaicism , Peroxisomes/genetics , Peroxisomes/metabolism , Refsum Disease, Infantile/genetics , Catalase/chemistry , Catalase/genetics , Cells, Cultured , Child, Preschool , Cholestasis/genetics , Cholestasis/pathology , Fibroblasts/pathology , Fluorescent Antibody Technique , Hot Temperature , Humans , Infant , Infant, Newborn , Male , Peroxisomes/pathology , Phenotype , Refsum Disease, Infantile/enzymology , Refsum Disease, Infantile/metabolism
3.
Biochim Biophys Acta ; 1763(12): 1733-48, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17055079

ABSTRACT

Defects in PEX genes impair peroxisome assembly and multiple metabolic pathways confined to this organelle, thus providing the biochemical and molecular bases of the peroxisome biogenesis disorders (PBD). PBD are divided into two types--Zellweger syndrome spectrum (ZSS) and rhizomelic chondrodysplasia punctata (RCDP). Biochemical studies performed in blood and urine are used to screen for the PBD. DNA testing is possible for all of the disorders, but is more challenging for the ZSS since 12 PEX genes are known to be associated with this spectrum of PBD. In contrast, PBD-RCDP is associated with defects in the PEX7 gene alone. Studies of the cellular and molecular defects in PBD patients have contributed significantly to our understanding of the role of each PEX gene in peroxisome assembly.


Subject(s)
Peroxisomal Disorders/metabolism , Peroxisomes/metabolism , Amino Acid Sequence , Chondrodysplasia Punctata, Rhizomelic/genetics , Chondrodysplasia Punctata, Rhizomelic/metabolism , Humans , Membrane Proteins/genetics , Membrane Proteins/metabolism , Molecular Sequence Data , Peroxisomal Disorders/diagnosis , Peroxisomal Disorders/genetics , Peroxisomes/genetics , Pipecolic Acids/metabolism , Plasmalogens/metabolism , Refsum Disease, Infantile/genetics , Refsum Disease, Infantile/metabolism , Zellweger Syndrome/genetics , Zellweger Syndrome/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...